



New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 3, Concourse Level, Empire State Plaza, Albany NY
February 27, 2025
10:30am to 3:30pm

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

10:30 – 10:45 Welcome and Introductions

10:45 – 11:45 Public Comment Period

11:45 – 12:15 Preferred Drug Program (PDP) Review

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include updates to clinical criteria or coverage parameters. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Fluoroquinolones - Oral
Previous Review Date: 9/20/2018

12:15 – 1:15 Lunch / Executive Session (PDP Financial Reviews)

1:15 – 1:45 Preferred Drug Program (PDP) Recommendations

1:45 – 3:15 Drug Utilization Review

1. The DUR Board will review the following drugs / drug classes and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

- a. Wegovy (semaglutide)

The review is a continuation from [October 25, 2024 DUR Board meeting](#) and only includes the following indication:
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.



Drug Utilization Review (continued)

2. The DUR Board will review the following drugs / drug categories that may be dispensed without a prescription (i.e. over-the-counter drugs that are dispensed with a fiscal order) and, if applicable, recommend coverage changes:
 - a. Gastrointestinal Products
 - Bismuth subsalicylate
 - b. Otic Products
 - Carbamide peroxide
 - c. Topicals Products
 - Menthol

3:15 – 3:30 Final Comments and Adjournment

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments during the DUR Board meeting, must complete the registration process by February 19, 2025. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical information can be sent to dur@health.ny.gov. Any studies cited should be referenced, with the primary source of funding included. Written statements should summarize key points and may not exceed two (2) pages in length. Written statements must be received by February 19, 2025. Any other clinical information must be received by February 12, 2025.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

DUR Board Members may participate by [videoconferencing from a non-public location under extraordinary circumstances](#) if unexpected factor or event precludes physical attendance.



Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall - Room 130
Buffalo, NY 14214

Department of Health – New York City Office
90 Church Street
New York, NY 10022
